View more on these topics

Best of health

Eaton Vance is one of the biggest independent investment management businesses in the US. It has more than $110bn under management but is hardly known in the UK. But it has recently made a number of its funds available here.

Some of these funds have excellent records. The one I like best is its worldwide health sciences fund, which has shown outstanding returns over the last 10 years, averaging over 15 per cent a year to October 31, 2005. Over the last three years – quite a difficult period – it has shown returns of over 16 per cent a year and over 10 per cent over the past year. The fund’s objective is to achieve long-term capital growth with a low portfolio turnover by investing in a worldwide and diversified selection of health sciences companies. It currently invests around 60 per cent in biotechnology stocks and 40 per cent in pharmaceuticals. Around 65 per cent is invested in US shares, with around 20 per cent in Europe and 15 per cent in the Far East. Among its top 10 holdings are Amgen, Nov- artis, Genetech, Genzyme Corporation, Takeda Pharmaceutical and Medimmune.

The fund is run by OrbiMed Advisors, which manages more than $5bn of assets focused exclusively on the healthcare sector. The management team is headed by Samuel Isaly, who has been running the fund since inception. He is assisted by 21 investment professionals, many of them with scientific expertise.

They believe in a strong sell discipline, which 80 per cent of the time is triggered by a more attractive buy and 20 per cent of the time by surpassing the valuation targets or in some cases underperforming. I believe the management team is the best in the world in its sector and this fund should certainly form part of all bigger growth portfolios.


Isa investors get risk appetite

Unconstrained, non-benchmarked investment trusts appealed to retail investors in the third-quarter, according to the Alliance Trust Savings Select Isa rankings. Caledonia investment trust was the top choice for the three months to October, moving up from third place in the second quarter and knocking the British Empire securities & general trust off the top spot. […]

Moneyquest appoints chairman to lead two-year expansion plan

Moneyquest has taken a key step in its plan to expand and challenge the leading mortgage broker firms with the appointment of its first chairman. Angus McSween will oversee the phone and online mortgage operation’s two-year plan and steer the company towards Aim listing. Managing director Steve Pollard and operations director Paul Reynolds aim to […]

Chadborn offering franchise scheme

IFA firm Chadborn Baker & Kearle is changing to a franchise-style business model. It is devolving ownership of the company’s three branches to local managers who will run the businesses under the Chadborn Baker & Kearle brand. CBK (Colchester), CBK (Nottingham) and CBK (Swansea) will operate autonomously within the wider CBK group. Principal Peter Chadborn […]

Occupational therapy

What remedies are available where HMRC diagnoses an interest in possession?

Spring has sprung

Well, it’s been lovely to see a little bit of sunshine, even if it was only a brief appearance. I live in Scotland so, believe me, it was very brief.  Of course, with even the tiniest hint of spring, thoughts turn to the inevitable clearout that must take place.  And that got me to thinking […]


News and expert analysis straight to your inbox

Sign up


    Leave a comment


    Why register with Money Marketing ?

    Providing trusted insight for professional advisers.  Since 1985 Money Marketing has helped promote and analyse the financial adviser community in the UK and continues to be the trusted industry brand for independent insight and advice.

    News & analysis delivered directly to your inbox
    Register today to receive our range of news alerts including daily and weekly briefings

    Money Marketing Events
    Be the first to hear about our industry leading conferences, awards, roundtables and more.

    Research and insight
    Take part in and see the results of Money Marketing's flagship investigations into industry trends.

    Have your say
    Only registered users can post comments. As the voice of the adviser community, our content generates robust debate. Sign up today and make your voice heard.

    Register now

    Having problems?

    Contact us on +44 (0)20 7292 3712

    Lines are open Monday to Friday 9:00am -5.00pm